Fibromyalgia – It Isn’t Just Pain.

HelpingHand I know a lot of people who suffer from some form of chronic pain, and alongside that, there are commonly many kinds of symptoms, which tend to get treated as if they are separate and completely unrelated. But it makes far more sense to look for a deeper, connecting cause.

“Fibromyalgia…is a chronic pain syndrome accompanied by other symptoms such as depression, anxiety, fatigue or sleep has…a greater presence in women than in men…Despite its high prevalence, its etiology is still unknown and there are no effective treatments.” (Mario D. Cordero, 2011)

Chronic pain can be a complex issue with a number of different driving forces and interconnected symptoms, but one thing that has been shown to be found at the heart of it all, is an underlying hypometabolic state.

People with ongoing and persistent pain issues, are sometimes told they have ‘fibromyalgia syndrome’ (FMS), and then given very little useful help or advice. Sadly, they are often told, and end up believing, that there really is ‘no effective treatment’. Other symptoms that coexist with the pain issues, are often disregarded or blamed on what are said to be separate issues, requiring unrelated specialized treatments. It’s good for business, and not so good for patients, and there is plenty of actual scientific (and logically coherent) evidence, suggesting a different story altogether.

““Fibromyalgia syndrome” (FMS) is the diagnosis clinicians most often give patients who have chronic widespread pain and abnormal tenderness. Most FMS researchers state that the etiology of the disorder is unknown. In doing so, they fail to account for a substantial line of evidence showing that the main mechanism of FMS is inadequate thyroid hormone regulation.” (John C. Lowe, Jackie Yellin, 2008)

Women suffer from FMS (as well as thyroid issues or hypo-metabolism) more commonly than men, and this is largely due to naturally greater exposure to estrogen, slower liver function, and a generally lower resting body temperature.

“Many features of fibromyalgia and hypothyroidism are virtually the same, and thyroid hormone treatment trials have reduced or eliminated fibromyalgia symptoms. These findings led the authors to test the hypothesis that fibromyalgia patients are hypometabolic compared to matched controls.” (Lowe JC et al., 2006)

“…women with FMS had significantly lower resting metabolic rates and basal body temperatures…consistent with too little thyroid hormone regulation of cell function…” (John C. Lowe, Jackie Yellin, 2008)

Recognizing the relationship between thyroid function and chronic pain or FMS, is a great place to start, however even when this does happen, many get told (after their thyroid system has been examined), that their thyroid function is normal.

And when they are diagnosed with thyroid issues, and if (as is often the case), the treatment does not make symptoms (including chronic pain) any better, they are led to believe that thyroid energy metabolism must not have been the underlying problem. This is most likely not an accurate and justified conclusion.

One important reason, is that when people are diagnosed with hypothyroidism, they are commonly treated with T4 (thyroxine, the inactive thyroid hormone), alone, for the purposes of hormone replacement. There is good reason to believe that this is often not an effective method (especially for women, due to natural biological differences reducing the ability to convert T4 into the active thyroid hormone), and that it can in fact make matters worse.

Tests sometimes show a buildup of T4 in the blood of hypothyroid women, especially when it is being supplemented, reflecting the fact that it is not being used to improve thyroid performance. One of the reasons for this, is that estrogen (as well as low thyroid function in general, as well as slow liver function, or suppressed body temperature), can interfere with the ability of the liver to convert T4 into active thyroid hormone, T3.

Over time then, attempts to improve thyroid metabolism, can sometimes be doing nothing more than further suppressing metabolic energy system function, ironically leading to a worsening of the chronic nature (and seriousness) of FMS type symptoms, which are being fuelled, most likely, by thyroid insufficiency.

Unfortunately however, a culture has been heavily promoted, which erroneously assumes that when thyroid related issues are suspected and tested for, they are being properly ruled out as a factor (or properly dealt with), including when it pertains to cases diagnosed as FMS.

It makes sense (from a logical perspective), and there is lots of good evidence which has demonstrated, that the most widely used modern methods, used to assess whether thyroid function is sub-optimal or not, lack genuine diagnostic meaning and accuracy.

“…a small percentage of hypothyroid FMS patients recover with T4 alone…For most patients to fully recover, however, they must use either combined T4/T3 therapy (with a 4:1 ratio of T4-to-T3) or T3 alone.” (John C. Lowe, Jackie Yellin, 2008)

Adding insult to injury, popular dietary recommendations, suggested to people who are suffering from symptoms of stress and hypo-metabolism (including FMS symptoms in general), can be explained to be exacerbating the progression of the illness, as well as even getting in the way of the potential effectiveness of less than optimal treatments (for example T4 alone), which, in the context of a pro-metabolic diet, might have more of a chance to help.

Polyunsaturated fats (PUFAs), including fish oils, are often recommended as being a ‘healthy’ alternative to animal fats, in many diet related treatment protocols for FMS (and related issues), regardless of the fact that there is a great deal of evidence, showing that the highly unstable and reactive nature of the PUFAs, powerfully promote inflammation, suppress metabolism, and are thereby part of the problem.

The PUFAs are well known to be a major factor damaging liver function and thyroid energy system performance in general, and so this can add fuel to the fire, when it comes to interference with the usefulness of supplementing with T4 alone to deal with FMS or thyroid issues.

The PUFAs get in the way of the ability of the liver to prevent circulating estrogen levels from increasing, and estrogen further suppresses thyroid metabolism, and directly or indirectly promotes a number of anti-metabolic stress substances (including serotonin, lactic acid and nitric oxide), which can all be seen to be an additional part of the whole problem.

The PUFAs, as well as activation of the stress system in general, can lead to temporary symptom improvement, and short term symptom reduction is often used as an argument to promote the most popular treatment and dietary approaches. But metabolic suppression is not the same as overall thyroid energy metabolism improvement, and long term metabolic damage tends to get ignored or misinterpreted.

FMS is an inflammatory condition associated with increased oxidative stress, and this is demonstrated in part by higher levels of exposure to the breakdown products of the polyunsaturated fats (due to lipid peroxidation), throughout the body.

“Skin biopsies from patients showed a significant mitochondrial dysfunction…and increased levels of oxidative stress….related to increased levels of inflammation…correlated with pain, the principal symptom of FM…findings may support the role of oxidative stress, mitochondrial dysfunction and inflammation as interdependent events in the pathophysiology of FM.” (Sánchez-Domínguez B, et al.,2015)

“…lipid peroxidation, one of the main consequences of oxidative stress, can interfere in the etiology of pain perception, either by induction of central or peripheral hyperalgesia…oxidative damage can cause a local reduction of nociceptors and thereby reduce the pain threshold.” (Andrei Pereira Pernambuco, et al.,2016)

Studies suggesting that so called iron deficiency is a factor causing FMS, are more likely misinterpretations of the symptoms of hypothyroidism, or overall energy system dysfunction (anemia for example), and this is another scenario where the likely treatment approach (iron supplementation or increased dietary iron intake), could have unintended negative consequences. Iron dysregulation and oxidative stress are closely connected issues that exacerbate each other.

Oxidative stress and the breakdown products of the PUFAs, can be seen as an important link between FMS and thyroid dysfunction, as well as a number of other largely overlooked connections which help explain the relationship between chronic pain and many kinds of metabolic diseases or conditions.

“…involvement of oxidative and antioxidative parameters and to evaluate the relation between fibromyalgia (FMS) and obstructive sleep apnea syndrome (OSAS)…In the OSAS + FMS group, CAT (catalase), SOD (superoxide dismutase), and GDX (glutathione peroxidase) were found to be statistically significantly lower and MDA (malondialdehyde) was found to be statistically significantly higher than in both the control group and the OSAS group…which indicated that oxidative stress might play a role in the pathophysiology of both diseases…” (Yildirim T, Alp R., 2017)

FMS symptoms and diabetes have been shown to be closely associated, and this makes sense in the context of the role of thyroid energy system suppression, and exposure to oxidative stress and the breakdown products of the PUFAs, in the promotion of insulin resistance, blood sugar dysregulation and other diabetes related problems.

“…the numbers of tender points, pain scores, and the prevalence of sleep disturbances, fatigue, and headaches were higher in this group of patients…Fibromyalgia is a common finding in patients with types 1 and 2 diabetes, and its prevalence could be related to control of the disease. As with other diabetes complications, FM might be prevented by improved control of blood glucose levels.” (Tishler M, et al., 2003)

The over consumption of PUFAs and difficult to digest grains, seeds, nuts, beans and legumes, as well as too much under cooked starchy and fibrous vegetables (and even certain fruits), can promote an overgrowth of bacteria in the intestines, particularly when metabolism is suppressed and digestion and liver function are already sluggish.

More exposure to bacteria, generally means an increase in endotoxin and serotonin release in the intestines, which can then lead to greater stress on the liver, eventually causing levels of estrogen circulating throughout the body, to rise. This can be a big factor in the worsening of inflammation, promoting further interference with thyroid function and metabolism, and escalation of FMS symptoms.

Tissue injury and inflammation cause more serotonin to be released into the system, and rising levels of serotonin are powerfully anti-metabolic, and have been directly implicated in the progression of chronic pain, and many of the other issues which often go along with it, including depression and anxiety.

“Peripheral tissue and nerve injury can lead to hyperalgesia, a state in which painful stimuli are perceived as more painful than normal. One major contributor to hyperalgesia is augmented sensitivity of primary nociceptive neurons, a phenomenon called peripheral sensitization…our results reveal a novel pain mechanism in which…5-HT [serotonin]…maintains central terminal sensitization by activation of presynaptic 5-HT3A receptors…” (Kim YS, et al., 2014)

A number of different things which lower exposure to serotonin, and help to promote overall metabolic function, have been used to successfully reduce pain, and a variety of other symptoms of fibromyalgia or FMS.

“…a novel antidepressant…mirtazapine was used…characterized by selective blockade of 5-HT2 and 5-HT3 [serotonin] receptors…for fibromyalgia…Intensity of pain, sleep disturbances, fatigue and other symptoms were measured…the majority…experienced…improvement…of > or = 40% reduced intensity of fibromyalgia symptoms as well as reduced severity of depression….suggests a common pathophysiology of depression and symptoms of fibromyalgia.” (Samborski W, et al., 2004)

A hypometabolic state and digestive distress tend to go hand in hand for a number of biologically logical reasons, and they can probably all be explained under the general blanket of excess metabolic stress. It’s likely not just a coincidence that inflammatory bowel issues such as IBS and SIBO have been shown to be involved in the progression of thyroid dysfunction and FMS.

“Up to 32% of patients with fibromyalgia are labelled as having IBS, and 81% report irregular bowel habits…a common finding in both fibromyalgia and IBS is…the presence of bacterial overgrowth…it is likely that endotoxin produces hyperalgesia…” (Pimentel M, et al., 2004)

Many of the substances which rise under stress, and which are also promoted by excess bacteria and endotoxin release (including serotonin, estrogen and nitric oxide) have been directly implicated in FMS and thyroid energy system dysfunction in general.

“Serotonin (5-HT) precursors such as tryptophan (5-HTP), drugs that release 5-HT…stimulate the HPA axis, indicating a stimulatory effect of serotonergic input on HPA axis function. Hyperfunction of the HPA axis could also reflect an elevated serotonergic tonus in…FMS patients.” (Neeck G, Crofford LJ, 2000)

“…NO [nitric oxide] can actively participate in the hyper sensitization in FM…the use of [nitric oxide] inhibitors can be a very plausible alternative for the treatment of painful symptoms such as those presented in FM syndrome.” (Andrei Pereira Pernambuco, et al., 2016)

Methylene Blue (MB) has been shown to provide protection from bacterial endotoxin, serotonin, estrogen and nitric oxide, and it is known to directly promote mitochondrial energy system (metabolic) function. MB has also been shown to inhibit prolactin (which is known to rise alongside increasing estrogen levels), and which has been demonstrated to be high in another chronic pain related condition, polymyalgia rheumatica (PMR).

“…chronic administration of MB has analgesic effects on acute nociception as well as on the orofacial inflammatory pain.” (Dondaş A, et al., 2013)

Under circumstances where sugar is being avoided (or where the use of sugar for energy production is being interfered with), levels of stress substances such as adrenaline and cortisol, generally increase, helping to move things in a direction, likely to become increasingly hypometabolic over time.

Sugar restriction promotes the release of polyunsaturated fats (PUFAs) out of storage as free fatty acids, aggravating inflammatory issues and causing an increase in oxidative stress issues. The polyunsaturated fats damage the liver, intensify problems associated with endotoxin, estrogen and serotonin, and interfere with thyroid hormone function and overall energy system metabolism, worsening general blood sugar dysregulation issues, further inhibiting the use of sugar for energy production. This is a vicious circle type of scenario, which can play a big part in the promotion of FMS.

In this type of circular scenario, the responsiveness of tissues to T3 can be significantly suppressed, adding to the difficulty of getting positive treatment results, at least in the short term. When T3 is ineffective, metabolic function starts to be driven largely by the stress system, rather than with proper energy system function, and this can be a major factor worsening chronic pain and related symptoms.

There are many different ways to approach the issue of chronic pain, and yet they are probably all interrelated one way or another. True biology, to the extent that it is understandable, is holistic in nature. In this sense fibromyalgia or FMS, is as much a brain issue, as it is an hormonal, nervous system or energy production problem.

A great example of this is the way that pain dysfunction is now being shown to be able to be treated with the use of ‘brain based’ therapies, such as neurological drills which tap into vestibular and ocular function, in an attempt to improve overall nervous system performance. Such methods can be said to work directly on the brain and nervous system, but in saying that, they can also be understood to be attempting to improve thyroid metabolism and energy systems, as well as liver and digestive function.

“Medical records of 124 patients (78 women, 46 men) were reviewed. Vestibular deficits were detected in 83 patients (66.9%)…Patients being treated with medications for chronic, noncancer pain or other underlying neurologic disorders may have a higher-than-average incidence of vestibular dysfunction.” (John W. Gilbert, et al., 2014)

Exposure to chronic stress can lead to many different ‘disease’ outcomes, with interrelated and overlapping physiological conditions, and symptomology. Fibromyalgia and chronic fatigue are sometimes considered to be expressions of the same underlying problems. High levels of nitric oxide, endotoxin, serotonin and estrogen, as well as hypo-metabolism in general, have all been implicated.

“…chronic fatigue syndrome (CFS), fibromyalgia (FM), multiple chemical sensitivity (MCS) and posttraumatic stress disorder (PTSD)…share common symptoms…Many patients meet the criteria for diagnosis for two or more of these disorders and each disorder appears to be often induced by…stress…followed by a chronic pathology…” (Pall ML, 2001)

Iron dysregulation, excess PUFAs in circulation, endotoxin, thyroid energy system suppression, and increased exposure to the substances of stress, such as serotonin, estrogen and nitric oxide, are interrelated and central to many metabolic diseases including diabetes, and can probably explain many cases of FMS and its co-occurance with a long list of symptoms.

In combination with pro-metabolic treatments, a diet avoiding the polyunsaturated fats, and limiting difficult to digest fibrous and starchy foods, including regular intake of milk, cheese and gelatin, sweet ripe fruits, fruit juice, white sugar, and honey, has the potential to help deal with the causes and symptoms of hypometabolism and thyroid dysfunction, including FMS or chronic pain issues.

Hypo-metabolism and irregularities in body temperature and pulse regulation go hand in hand. Measuring and tracking temperature and pulse variations (commonly upon waking and after breakfast and lunch), as well as other old fashioned reliable indicators of thyroid function, can help determine the success of attempts to improve thyroid and metabolism, and help understand the impact of changes in diet (and other therapeutic methods) being experimented with, and provide useful information which can increase the chances of healing and recovery.

“…likely that too little thyroid hormone regulation of cell function is the main cause of most patients’ ignore the evidence…is…not respectable scientific conduct.” (John C. Lowe, Jackie Yellin, 2008)

Some pro metabolism things which have had success in treating pain related conditions, include thiamine (B1), red light therapy (also in combination with MB), aspirin, activated charcoal, cyproheptadine, low dose naltrexone, progesterone, magnesium and certain antibiotics.

Although I am not a doctor or health professional, and none of this is intended as treatment advice, I have seen a lot of different types of evidence, which have convinced me of the value in approaches (to FMS and related symptoms), which work on metabolic improvement, in the true sense.

In line with the same pro-metabolism outlook, evidence and explanations show the reasons why popular anti-depressants (such as the SSRI’s) and many current and commonly prescribed pain medications, have at the very least, been far from successful.

See more here

Thyroid Science. 2008; 3(6):R1-14. Inadequate Thyroid Hormone Regulation as the Main Mechanism of Fibromyalgia: A Review of the Evidence. John C. Lowe, Jackie Yellin.

Neuron. 2014 Feb 19; 81(4): 873–887. Central terminal sensitization of TRPV1 by descending serotonergic facilitation modulates chronic pain. Kim YS, Chu Y, Han L, Li M, Li Z, LaVinka PC, Sun S, Tang Z, Park K, Caterina MJ, Ren K, Dubner R, Wei F, Dong X.

Pharmacol. 2011. The complex role of serotonin and 5-HT receptors in chronic pain. Bardin L. Behav.

Molecular Neurobiology. , Volume 30, Issue 30, pp 117–125. Serotonin in pain and analgesia. Claudia Sommer

Proc Natl Acad Sci. 2016 Jun 14; 113(24): E3441–E3450. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Grace PM, Strand KA, Galer EL, Urban DJ, Wang X, Baratta MV, Fabisiak TJ, Anderson ND, Cheng K, Greene LI, Berkelhammer D, Zhang Y, Ellis AL, Yin HH, Campeau S, Rice KC, Roth BL, Maier SF, Watkins LR.

Gynecol Endocrinol. 2003 Feb;17(1):79-85. Thyroid function and postmenopause. Schindler AE

J Clin Invest. 2017; 127(4): 1370-1374. Prostaglandin-mediated inhibition of serotonin signaling controls the affective component of inflammatory pain. Anand Kumar Singh, Joanna Zajdel, Elahe Mirrasekhian, Nader Almoosawi, Isabell Frisch, Anna M. Klawonn, Maarit Jaarola, Michael Fritz, and David Engblom

eLife. 2014; 3: e03896. Reinstatement of long-term memory following erasure of its behavioral and synaptic expression in Aplysia. Chen S, Cai D, Pearce K, Sun PY, Roberts AC, Glanzman DL.

Clin J Pain. 2014 Jun; 30(6): 544–555. Review of overlap between thermoregulation and pain modulation in fibromyalgia. Larson AA, Pardo JV, Pasley JD.

Arthritis Rheum. 1995 Jan;38(1):19-28. The prevalence and characteristics of fibromyalgia in the general population. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L.

J Headache Pain. 2013; 14(Suppl 1): P86. Repeated methylene blue administration produces analgesia in experimental pain. A Dondas, A Luca, T Alexa,VA Grigoras, OC Mungiu, and CR Bohotin

Rheumatology, Volume 41, Issue 4, April 2002, Pages 423–429, In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers.  R. H. Straub J. Georgi K. Helmke P. Vaith B. Lang

Front Physiol. 2014; 5: 306. Low-level laser therapy as a treatment for chronic pain. Kingsley JD, Demchak T, Mathis R.

MOJ Orthop Rheumatol. 2015; 2(5): 00068. The Use of Low Level Laser Therapy (LLLT) For Musculoskeletal Pain. Cotler HB, Chow RT, Hamblin MR, Carroll J.

Arthritis Res Ther. 2015; 17: 360. The effectiveness of low-level laser therapy for nonspecific chronic low back pain: a systematic review and meta-analysis. Huang Z, Ma J, Chen J, Shen B, Pei F, Kraus VB.

Front Neurol. 2017; 8: 23. Inaccurate Saccades and Enhanced Vestibulo-Ocular Reflex Suppression during Combined Eye–Head Movements in Patients with Chronic Neck Pain: Possible Implications for Cervical Vertigo. Johnston JL, Daye PM, Thomson GT.

The Journal of the American Osteopathic Association, March 2014, Vol. 114, 172-178. Vestibular Dysfunction in Patients With Chronic Pain or Underlying Neurologic Disorders. John W. Gilbert, MD; Manuel Vogt, DO; Robert E. Windsor, MD; Gregory E. Mick, DO; Gay B. Richardson, MD; Benjamin B. Storey, MD; Stephanie L. Herder, MD; Susan Ledford, AA; Dee A. Abrams, PA-C; Mary Katherine Theobald, RN; Dana Cunningham, CMA; Louise Kelly, PA-C; Kimberly V. Herring, RN, ADN, BSN; Michael L. Maddox, BA

Rheum Dis Clin North Am. 2000 Nov;26(4):989-1002. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Neeck G, Crofford LJ.

BMJ Case Rep. 2013 May 20;2013. pii: bcr2013009019. High-dose thiamine improves the symptoms of fibromyalgia. Costantini A, Pala MI, Tundo S, Matteucci P.

Clin Rheumatol. 2010 Dec;29(12):1403-12. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernández-Bustillo E, Hollenberg MD.

Rocz Akad Med Bialymst. 2004;49:265-9. Effects of antidepressant mirtazapine on fibromyalgia symptoms. Samborski W, Lezańska-Szpera M, Rybakowski JK.

Cell Biochem Biophys. 2011 Sep;61(1):23-31. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. Shen L, Shen J, Pu J, He B.

J Integr Med. 2015 Sep;13(5):306-13. Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study. Engen DJ, McAllister SJ, Whipple MO, Cha SS, Dion LJ, Vincent A, Bauer BA, Wahner-Roedler DL.

Metabolic features of chronic fatigue syndrome. Robert K. Naviaux, Jane C. Naviaux, Kefeng Li, A. Taylor Bright, William A. Alaynick, Lin Wang, Asha Baxter, Neil Nathan, Wayne Anderson, and Eric Gordon.

Pain Med. 2008 Apr;9(3):365-70. Insular hypometabolism in a patient with fibromyalgia: a case study. Wood PB, Patterson JC 2nd, Jasmin LD.

JCI Insight. 2016 Dec 22;1(21):e89376. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. Fluge Ø, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, Rekeland IG, Sapkota D, Røsland GV, Fosså A, Ktoridou-Valen I, Lunde S, Sørland K, Lien K, Herder I, Thürmer H, Gotaas ME, Baranowska KA, Bohnen LM, Schäfer C, McCann A, Sommerfelt K, Helgeland L, Ueland PM, Dahl O, Tronstad KJ.

Cell Biochem Funct. 2009 Jun;27(4):181-5. Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia. Akkuş S, Naziroğlu M, Eriş S, Yalman K, Yilmaz N, Yener M.

J Thyroid Res. 2011;2011:875125. Role of Estrogen in Thyroid Function and Growth Regulation. Santin AP, Furlanetto TW.

Med Hypotheses. 2001 Aug;57(2):139-45. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Pall ML.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1033-41. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE.

Front Biosci (Schol Ed). 2011 Jan 1;3:474-86. The endocrinology of perimenopause: need for a paradigm shift. Prior JC, Hitchcock CL.

J Clin Invest. 1993 Oct;92(4):1896-902. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimophism of the stress response and immune/inflammatory reaction. Vamvakopoulos NC, Chrousos GP.

Fibrom open 2016, Vol 1(1): 105. Involvement of Oxidative Stress and Nitric Oxide in Fibromyalgia Pathophysiology: A Relationship to be Elucidated. Andrei Pereira Pernambuco, Luana Pereira Leite Schetino, Luciana De Souza Cota Carvalho and Débora D’Ávila Reis.

PLoS One. 2011;6(10):e26915. Clinical Symptoms in Fibromyalgia Are Better Associated to Lipid Peroxidation Levels in Blood Mononuclear Cells Rather than in Plasma. Cordero MD, Alcocer-Gómez E, Cano-García FJ, De Miguel M, Carrión AM, Navas P, Sánchez Alcázar JA.

Nature Reviews Rheumatology. 2015; volume 11, pages 513–520. The role of sleep in pain and fibromyalgia. Ernest H. S. Choy.

Med Sci Monit. 2006 Jul;12(7):CR282-9. Female fibromyalgia patients: lower resting metabolic rates than matched healthy controls. Lowe JC, Yellin J, Honeyman-Lowe G.

Reumatol Clin. 2011;7(5):281–283. Oxidative Stress in Fibromyalgia: Pathophysiology and Clinical Implications. Mario D. Cordero

J Clin Psychiatry 2015;76(12):1658–1667. Oxidative Stress and Antioxidant Parameters in Patients With Major Depressive Disorder Compared to Healthy Controls Before and After Antidepressant Treatment: Results From a Meta-Analysis. Sara Jiménez-Fernández, MD; Manuel Gurpegui, MD; Francisco Díaz-Atienza, MD; Lucía Pérez-Costillas, MD; Miriam Gerstenberg, MD; and Christoph U. Correll, MD

J Laryngol Otol. 2010 Jun;124(6):610-5. Vestibular evoked myogenic potentials in patients with fibromyalgia syndrome. Bayazit YA, Celenk F, Gunduz AG, Gunduz B, Ondag N, Meray J.

Biomedicines. 2017 Apr 11;5(2). pii: E15. Modulation of NMDA Receptor Activity in Fibromyalgia. Littlejohn G, Guymer E.

Ann Rheum Dis. 2004 Apr;63(4):450-2. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC.

Mitochondrion. 2015 Mar;21:69-75. Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with Fibromyalgia. Sánchez-Domínguez B, Bullón P, Román-Malo L, Marín-Aguilar F, Alcocer-Gómez E, Carrión AM, Sánchez-Alcazar JA, Cordero MD.

Eur Spine J. 2013 Apr;22(4):697-707. Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacy. Albert HB, Sorensen JS, Christensen BS, Manniche C.

Rheumatol Int. 2003 Sep;23(5):211-5. Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes. Endresen GK.

World J Gastroenterol. 2010 Jun 28;16(24):2978-90. Small intestinal bacterial overgrowth syndrome. Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M.

Rheumatol Int. 2003 Jul;23(4):171-3. Fibromyalgia in diabetes mellitus. Tishler M, Smorodin T, Vazina-Amit M, Ramot Y, Koffler M, Fishel B.

Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):293-304. Management of functional abdominal pain and irritable bowel syndrome in children and adolescents. Chiou E, Nurko S.

Minerva Pediatr. 2008 Dec;60(6):1367-74. Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebo-controlled trial. Sadeghian M, Farahmand F, Fallahi GH, Abbasi A.

J Orofac Pain. 2000 Winter;14(1):37-46. Plasma and Serum Serotonin Levels and their Relationship to Orofacial Pain and Anxiety in Fibromyalgia. Ernberg M, Voog U, Alstergren P, Lundeberg T, Kopp S.

Pediatric Annals. 2017;46(3):e120-e125 Cyproheptadine: A Potentially Effective Treatment for Functional Gastrointestinal Disorders in Children. Amornluck Krasaelap, MD; Shailender Madani, MD

Physiol Res. 1993;42(3):171-4. Anterior pituitary weight, cAMP, cGMP and prolactin levels after combined treatment with estradiol and methylene blue. Schreiber V, Nedvídková J, Jahodová J.

Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):20-29. The role of oxidative stress in the relation between fibromyalgia and obstructive sleep apnea syndrome. Yildirim T, Alp R.

Am J Nephrol. 2013;37(6):518-25. Oral activated charcoal adsorbent (AST-120) ameliorates CKD-induced intestinal epithelial barrier disruption. Vaziri ND, Yuan J, Khazaeli M, Masuda Y, Ichii H, Liu S.

Pain Ther. 2013 Dec;2(2):75-86. The Physiologic Effects of Pain on the Endocrine System. Tennant F.

PLoS One. 2019 May 6;14(5):e0216079. Is insulin resistance the cause of fibromyalgia? A preliminary report. Pappolla MA, Manchikanti L, Andersen CR, Greig NH, Ahmed F, Fang X, Seffinger MA, Trescot AM.

Arthritis Rheum. 2013 Feb;65(2):529-38. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Younger J, Noor N, McCue R, Mackey S.

Curr Rheumatol Rev. 2018;14(2):177-180. Low Dose Naltrexone in the Treatment of Fibromyalgia. Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG.

Physical Therapy, Volume 88, Issue 6, 1 June 2008, Pages 757–765. Misdiagnosis of Serotonin Syndrome as Fibromyalgia and the Role of Physical Therapists. Gregory M Alnwick.

Sao Paulo Med J. 2015 Sep-Oct;133(5):454. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Riera R.

Cell. 2015 Apr 9;161(2):264-76. Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY.


Image: Jagran Junction: Aapki Awaaz, Aapka Blog: “Social Issues Blog”
Artist: Unknown

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

Please "like" us:Already liked? You can close this